Revolution Medicines, Inc. <RVMD.O>: Morgan Stanley initiates coverage with overweight rating; price target $255
RVMD•Related News
MORNING BID AMERICAS-Forever war?
SPY•
FDA places partial clinical hold on Biohaven BHV-7000 epilepsy trial, halting new enrollment
BHVN•
ITT to present at D.A. Davidson Diversified Industrials & Services Conference
ITT•
Designer Brands Q2 Gross Profit USD 365.4 Million
DBI•
Signet Jewelers Limited <SIG.N>: Wells Fargo raises target price to $100 from $90
SIG•